T. Rowe Price Investment Management, Inc. Xenon Pharmaceuticals Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 1,437,831 shares of XENE stock, worth $57.1 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
1,437,831
Previous 1,503,808
4.39%
Holding current value
$57.1 Million
Previous $59.2 Million
4.8%
% of portfolio
0.03%
Previous 0.04%
Shares
5 transactions
Others Institutions Holding XENE
# of Institutions
219Shares Held
70.4MCall Options Held
109KPut Options Held
2.1K-
Avoro Capital Advisors LLC New York, NY5.67MShares$225 Million3.24% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.52MShares$180 Million1.73% of portfolio
-
Wellington Management Group LLP Boston, MA3.78MShares$150 Million0.03% of portfolio
-
Braidwell LP Stamford, CT2.91MShares$116 Million6.4% of portfolio
-
Janus Henderson Group PLC London, X02.87MShares$114 Million0.06% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.47B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...